The Lancet Neurology: Cannabidiol in Patients with Treatment-Resistant Epilepsy
The Lancet Neurology: Cannabidiol in Patients with Treatment-Resistant Epilepsy: An Open-Label Interventional Trial
The Lancet Neurology:
In December 2015, an open-label study of an oral cannabidiol (CBD) product (Epidiolex®) showed significantly reduced seizure frequency in children and young adults with multiple forms of drug-resistant epilepsy, including Dravet Syndrome and Lennox-Gastaut Syndrome. CBD was added to existing anti-epileptic treatment regimens. The study took place at over 11 epilepsy centers across the United States, and included 162 patients in the safety and tolerability analysis and 137 patients in the efficacy analysis. The results showed a median 36.5% reduction in monthly motor seizures. Over 12 weeks, the median monthly frequency of motor seizure fell from 30.0 to 15.8. Overall, CBD was shown to have a sufficient safety profile and was well-tolerated. Adverse events reported in more than 10% of patients included: somnolence (n=41 [25%]), decreased appetite (n=31 [19%]), diarrhea (n=31 [19%]), fatigue (n=21 [13%]), and convulsion (n=18 [11%]). Five (3%) patients discontinued treatment due to an adverse event.
Source: The Lancet Neurology